{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Active+Control&page=2", "query": { "condition": "Active Control", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Active+Control&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-03T23:06:08.095Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02326740", "title": "An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pyoderma Gangrenosum" ], "interventions": [ { "name": "gevokizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "gevokizumab open-label", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "XOMA (US) LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-12", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 7, "location_summary": "Oceanside, California • Tampa, Florida • Macon, Georgia + 4 more", "locations": [ { "city": "Oceanside", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Macon", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Henderson", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326740" }, { "nct_id": "NCT02451748", "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lab Work", "type": "OTHER" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)", "type": "DRUG" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Medrol", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "humira", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-08", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451748" }, { "nct_id": "NCT02383043", "title": "Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Active Cocaine Users" ], "interventions": [ { "name": "Cocaine", "type": "DRUG" }, { "name": "Sustained Release d-Amphetamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joshua A. Lile, Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "21 Years to 45 Years" }, "enrollment_count": 18, "start_date": "2015-02-01", "completion_date": "2018-04-05", "has_results": true, "last_update_posted_date": "2019-04-11", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02383043" }, { "nct_id": "NCT00454389", "title": "A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "Epi-Rad90™ Ophthalmic System", "type": "DEVICE" }, { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "NeoVista", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 494, "start_date": "2007-04", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2011-07-27", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00454389" }, { "nct_id": "NCT05453578", "title": "A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bacterial Disease Carrier", "Cystic Fibrosis" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "WRAIR-PAM-CF1", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2022-10-03", "completion_date": "2025-04-10", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 19, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05453578" }, { "nct_id": "NCT02794285", "title": "Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Active Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Anifrolumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 559, "start_date": "2016-06-30", "completion_date": "2021-12-21", "has_results": true, "last_update_posted_date": "2023-01-13", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 62, "location_summary": "Birmingham, Alabama • El Cajon, California • Hemet, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "El Cajon", "state": "California" }, { "city": "Hemet", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02794285" }, { "nct_id": "NCT06864026", "title": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriatic Arthritis", "Overweight or Obesity" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-03-06", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 53, "location_summary": "Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more", "locations": [ { "city": "Avondale", "state": "Arizona" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06864026" }, { "nct_id": "NCT02137226", "title": "BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "BI 695501", "type": "DRUG" }, { "name": "US-licensed Humira®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 645, "start_date": "2015-01-26", "completion_date": "2016-10-18", "has_results": true, "last_update_posted_date": "2018-01-19", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 63, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Glendale, Arizona + 51 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02137226" }, { "nct_id": "NCT00109408", "title": "A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "tocilizumab [RoActemra/Actemra]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 673, "start_date": "2005-07", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 70, "location_summary": "Montgomery, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 63 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109408" }, { "nct_id": "NCT03351608", "title": "Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neuromuscular Blockade" ], "interventions": [ { "name": "Sugammadex 2 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 4 mg/kg", "type": "DRUG" }, { "name": "Neostigmine + Glycopyrrolate", "type": "DRUG" }, { "name": "Neostigmine + Atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "2 Years to 16 Years" }, "enrollment_count": 288, "start_date": "2018-02-12", "completion_date": "2020-01-28", "has_results": true, "last_update_posted_date": "2021-02-05", "last_synced_at": "2026-09-03T23:06:08.095Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03351608" } ] }